ペプチドベースの代謝疾患治療薬の世界市場レポート 2025年

ペプチドベースの代謝疾患治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.8％で598億5,000万米ドルに成長します。予測期間の成長は、新規ペプチドアナログの開発、代謝性疾患に対する研究開発投資の増加、精密医療アプローチの採用、新興国市場の拡大、医薬品開発における共同研究や提携、ドラッグデリバリー技術の進歩、患者中心の治療への注力などに起因すると考えられます。予測期間における主な動向としては、創薬における人工知能の応用、個別化治療の拡大、遺伝子治療におけるCRISPR/Cas9の活用、患者モニタリングのためのウェアラブルデバイスの統合、経口ペプチド製剤の開発、疾病管理におけるデジタル治療薬の台頭、個別化治療のためのバイオバンクの拡大などが挙げられます。

肥満の有病率の増加は、ペプチドベースの代謝異常治療市場の成長を促進すると予想されます。肥満は体脂肪の過剰蓄積を特徴とする病状であり、重大な健康リスクをもたらします。肥満の罹患率の増加は、座りがちなライフスタイル、不健康な食習慣、遺伝的素因、カロリーの高い食事や運動不足を助長する環境の影響などの要因に起因しています。ペプチドベースの代謝異常治療薬は、ペプチドを使用して代謝機能を調節し、インスリン感受性を高め、食欲をコントロールすることにより、患者の転帰を改善し、慢性代謝疾患に伴う長期的な健康リスクを軽減することで、肥満などの状態を管理することに焦点を当てています。例えば、2024年4月、英国を拠点とするヘルスケア慈善団体である英国糖尿病協会は、英国では440万人が糖尿病とともに生活しており、さらに120万人が2型糖尿病と診断されていない可能性があると報告しました。2022年から2023年にかけての登録者数は、前年に比べ16万7,822人増加しています。その結果、肥満の有病率の上昇がペプチドベースの代謝障害治療薬市場の成長を促進しています。

ペプチドベースの代謝異常治療薬市場の主要企業は、アンメット・メディカル・ニーズに対応し、患者の治療選択肢を広げるため、ペプチドベースの抗糖尿病薬のバイオシミラー版など、革新的な治療法の開発に注力しています。ペプチドベースの抗糖尿病薬バイオシミラーは、既存の糖尿病ペプチド治療薬を複製したもので、同様の有効性と安全性プロファイルを、競合価格戦略により潜在的な低コストで提供します。例えば、インドに本社を置くグレンマーク・ファーマシューティカルズ社は、2024年1月にGLP-1受容体作動薬に属する一般的な抗糖尿病薬であるリラグルチドのバイオシミラーであるリラフィットを発売しました。これらの薬剤は、血糖値の調整に重要な天然のGLP-1ホルモンの作用を模倣します。臨床試験において、リラフィットは血糖コントロールの改善、体重減少の促進、心血管安全性の向上に有効であることが実証されており、これらは糖尿病、肥満、および関連する心血管疾患の管理において重要な利点です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ペプチドベースの代謝疾患治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のペプチドベースの代謝疾患治療薬市場：成長率分析
• 世界のペプチドベースの代謝疾患治療薬市場の実績：規模と成長, 2019-2024
• 世界のペプチドベースの代謝疾患治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ペプチドベースの代謝疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のペプチドベースの代謝疾患治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リラグルチド
• エキセナチド
• その他の薬剤の種類
• 世界のペプチドベースの代謝疾患治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リソソーム蓄積症
• 糖尿病
• 肥満
• 高コレステロール血症
• その他の用途
• 世界のペプチドベースの代謝疾患治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のペプチドベースの代謝疾患治療薬市場リラグルチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サクセンダ
• ヴィクトザ
• ジェネリックリラグルチド
• 2型糖尿病に対するリラグルチド
• 肥満に対するリラグルチド
• 世界のペプチドベースの代謝疾患治療薬市場エクセナチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビエッタ
• ビデュレオン
• 2型糖尿病に対するエキセナチド
• 徐放性エキセナチド
• ジェネリックエキセナチド
• 世界のペプチドベースの代謝疾患治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セマグルチド
• デュラグルチド
• アルビグルチド
• リキシセナチド
• GLP-1受容体作動薬
• プラムリンタイド
• 代謝障害に対するその他のペプチドベースの薬剤

第7章 地域別・国別分析

• 世界のペプチドベースの代謝疾患治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のペプチドベースの代謝疾患治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ペプチドベースの代謝疾患治療薬市場：競合情勢
• ペプチドベースの代謝疾患治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Eli Lilly Company
• Amgen Inc.
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ペプチドベースの代謝疾患治療薬市場2029：新たな機会を提供する国
• ペプチドベースの代謝疾患治療薬市場2029：新たな機会を提供するセグメント
• ペプチドベースの代謝疾患治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Peptide-based therapeutics for metabolic disorders are pharmaceutical treatments derived from short chains of amino acids, known as peptides. These therapies target and modulate biological pathways involved in conditions such as diabetes, obesity, and related disorders. Their primary objectives include regulating hormone levels, improving insulin sensitivity, managing appetite, and controlling glucose metabolism, all aimed at enhancing patient outcomes and quality of life.

Key drugs in the peptide-based treatment of metabolic disorders include liraglutide, exenatide, and others. Liraglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of natural GLP-1. This hormone regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion. Liraglutide is utilized in the treatment of conditions such as lysosomal storage diseases, diabetes, obesity, hypercholesterolemia, among others. Distribution channels for these therapies include hospital pharmacies, retail pharmacies, and online pharmacies.

The peptide based metabolic disorders therapeutics market research report is one of a series of new reports from the business research company that provides peptide based metabolic disorders therapeutics market statistics, including peptide based metabolic disorders therapeutics industry global market size, regional shares, competitors with an peptide based metabolic disorders therapeutics market share, detailed peptide based metabolic disorders therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide based metabolic disorders therapeutics industry. This peptide based metabolic disorders therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide based metabolic disorders therapeutics market size has grown rapidly in recent years. It will grow from $29.89 billion in 2024 to $34.4 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to the increasing prevalence of metabolic disorders, advancements in peptide synthesis technologies, rising healthcare expenditure, a growing aging population, an expanding biopharmaceutical sector, regulatory approvals for new therapies, and increasing awareness about personalized medicine.

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $59.85 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to the development of novel peptide analogs, rising R&D investments in metabolic disorders, adoption of precision medicine approaches, expansion of emerging markets, collaborations and partnerships in drug development, advancements in delivery technologies, and focus on patient-centric therapies. Major trends in the forecast period include the application of artificial intelligence in drug discovery, the growth of personalized therapies, the utilization of CRISPR/Cas9 for genetic therapies, the integration of wearable devices for patient monitoring, the development of oral peptide formulations, the rise of digital therapeutics in disease management, and the expansion of biobanking for personalized treatments.

The increasing prevalence of obesity is expected to drive the growth of the peptide-based metabolic disorders therapeutic market. Obesity is a medical condition characterized by excessive body fat accumulation, which poses significant health risks. The rising incidence of obesity is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, genetic predisposition, and environmental influences that encourage calorie-rich diets and physical inactivity. Peptide-based therapeutics for metabolic disorders focus on managing conditions like obesity by using peptides to regulate metabolic functions, enhance insulin sensitivity, and control appetite, thereby improving patient outcomes and reducing the long-term health risks associated with chronic metabolic conditions. For instance, in April 2024, the British Diabetic Association, a UK-based healthcare charity, reported that 4.4 million people in the UK are living with diabetes, with an additional 1.2 million potentially undiagnosed with type 2 diabetes. The 2022-2023 registration figures show an increase of 167,822 compared to the previous year. Consequently, the rising prevalence of obesity is propelling the growth of the peptide-based metabolic disorders therapeutics market.

Leading companies in the peptide-based metabolic disorders therapeutic market are focusing on developing innovative treatments, such as biosimilar versions of peptide-based anti-diabetic drugs, to address unmet medical needs and broaden treatment options for patients. Peptide-based anti-diabetic biosimilars replicate existing peptide therapies for diabetes, offering similar efficacy and safety profiles at potentially lower costs through competitive pricing strategies. For instance, Glenmark Pharmaceuticals Ltd., based in India, launched Lirafit in January 2024, a biosimilar of Liraglutide, a popular anti-diabetic medication belonging to the GLP-1 receptor agonist class. These drugs mimic the action of the natural GLP-1 hormone, crucial for regulating blood sugar levels. Clinical trials have demonstrated Lirafit's effectiveness in improving glycemic control, promoting weight loss, and enhancing cardiovascular safety, which are critical benefits in managing diabetes, obesity, and related cardiovascular conditions.

In December 2023, Roche Holding AG, a healthcare company based in Switzerland, completed the acquisition of Carmot Therapeutics Inc. for $2.7 billion. Through this transaction, Roche secures access to Carmot's clinical-stage incretins, including CT-388, a dual GLP-1/GIP receptor agonist currently in Phase 2 trials. This compound holds promise for treating obesity in both diabetic and non-diabetic patients. Carmot Therapeutics Inc., a clinical-stage biotechnology firm, focuses on developing peptide-based therapeutics primarily aimed at metabolic disorders such as diabetes and obesity.

Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide based metabolic disorders therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide-based metabolic disorders therapeutics market consists of sales of semaglutide, dulaglutide, albiglutide, and pramlintide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Based Metabolic Disorders Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide based metabolic disorders therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide based metabolic disorders therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide based metabolic disorders therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Liraglutide; Exenatide; Other Drug Type
• 2) By Application: Lysosomal Storage Diseases; Diabetes; Obesity; Hypercholesterolemia; Other Applications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Liraglutide: Brand: Saxenda; Brand: Victoza; Generic Liraglutide; Liraglutide For Type 2 Diabetes; Liraglutide For Obesity
• 2) By Exenatide: Brand: Byetta; Brand: Bydureon; Exenatide For Type 2 Diabetes; Extended-Release Exenatide; Generic Exenatide
• 3) By Other Drug Type: Semaglutide; Dulaglutide; Albiglutide; Lixisenatide; GLP-1 Receptor Agonists; Pramlintide; Other Peptide-Based Drugs For Metabolic Disorders
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide Based Metabolic Disorders Therapeutics Market Characteristics

3. Peptide Based Metabolic Disorders Therapeutics Market Trends And Strategies

4. Peptide Based Metabolic Disorders Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Peptide Based Metabolic Disorders Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Peptide Based Metabolic Disorders Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Peptide Based Metabolic Disorders Therapeutics Market Growth Rate Analysis
• 5.4. Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Peptide Based Metabolic Disorders Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Peptide Based Metabolic Disorders Therapeutics Total Addressable Market (TAM)

6. Peptide Based Metabolic Disorders Therapeutics Market Segmentation

• 6.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liraglutide
• Exenatide
• Other Drug Type
• 6.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lysosomal Storage Diseases
• Diabetes
• Obesity
• Hypercholesterolemia
• Other Applications
• 6.3. Global Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Peptide Based Metabolic Disorders Therapeutics Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Saxenda
• Victoza
• Generic Liraglutide
• Liraglutide For Type 2 Diabetes
• Liraglutide For Obesity
• 6.5. Global Peptide Based Metabolic Disorders Therapeutics Market, Sub-Segmentation Of Exenatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Byetta
• Bydureon
• Exenatide For Type 2 Diabetes
• Extended-Release Exenatide
• Generic Exenatide
• 6.6. Global Peptide Based Metabolic Disorders Therapeutics Market, Sub-Segmentation Of Other Drug Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Semaglutide
• Dulaglutide
• Albiglutide
• Lixisenatide
• GLP-1 Receptor Agonists
• Pramlintide
• Other Peptide-Based Drugs For Metabolic Disorders

7. Peptide Based Metabolic Disorders Therapeutics Market Regional And Country Analysis

• 7.1. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Peptide Based Metabolic Disorders Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market

• 8.1. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide Based Metabolic Disorders Therapeutics Market

• 9.1. China Peptide Based Metabolic Disorders Therapeutics Market Overview
• 9.2. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide Based Metabolic Disorders Therapeutics Market

• 10.1. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide Based Metabolic Disorders Therapeutics Market

• 11.1. Japan Peptide Based Metabolic Disorders Therapeutics Market Overview
• 11.2. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide Based Metabolic Disorders Therapeutics Market

• 12.1. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide Based Metabolic Disorders Therapeutics Market

• 13.1. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide Based Metabolic Disorders Therapeutics Market

• 14.1. South Korea Peptide Based Metabolic Disorders Therapeutics Market Overview
• 14.2. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide Based Metabolic Disorders Therapeutics Market

• 15.1. Western Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
• 15.2. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide Based Metabolic Disorders Therapeutics Market

• 16.1. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide Based Metabolic Disorders Therapeutics Market

• 17.1. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide Based Metabolic Disorders Therapeutics Market

• 18.1. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide Based Metabolic Disorders Therapeutics Market

• 19.1. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide Based Metabolic Disorders Therapeutics Market

• 20.1. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market

• 21.1. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market Overview
• 21.2. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide Based Metabolic Disorders Therapeutics Market

• 22.1. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide Based Metabolic Disorders Therapeutics Market

• 23.1. North America Peptide Based Metabolic Disorders Therapeutics Market Overview
• 23.2. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide Based Metabolic Disorders Therapeutics Market

• 24.1. USA Peptide Based Metabolic Disorders Therapeutics Market Overview
• 24.2. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide Based Metabolic Disorders Therapeutics Market

• 25.1. Canada Peptide Based Metabolic Disorders Therapeutics Market Overview
• 25.2. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide Based Metabolic Disorders Therapeutics Market

• 26.1. South America Peptide Based Metabolic Disorders Therapeutics Market Overview
• 26.2. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide Based Metabolic Disorders Therapeutics Market

• 27.1. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide Based Metabolic Disorders Therapeutics Market

• 28.1. Middle East Peptide Based Metabolic Disorders Therapeutics Market Overview
• 28.2. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide Based Metabolic Disorders Therapeutics Market

• 29.1. Africa Peptide Based Metabolic Disorders Therapeutics Market Overview
• 29.2. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Peptide Based Metabolic Disorders Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Peptide Based Metabolic Disorders Therapeutics Market Competitive Landscape
• 30.2. Peptide Based Metabolic Disorders Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Peptide Based Metabolic Disorders Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. GlaxoSmithKline plc
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Eli Lilly Company
• 31.9. Amgen Inc.
• 31.10. Gilead Sciences Inc.
• 31.11. Novo Nordisk A/S
• 31.12. Teva Pharmaceutical Industries Ltd.
• 31.13. Regeneron Pharmaceuticals Inc.
• 31.14. Biogen Inc.
• 31.15. Vertex Pharmaceuticals Incorporated

32. Global Peptide Based Metabolic Disorders Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide Based Metabolic Disorders Therapeutics Market

34. Recent Developments In The Peptide Based Metabolic Disorders Therapeutics Market

35. Peptide Based Metabolic Disorders Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Peptide Based Metabolic Disorders Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Peptide Based Metabolic Disorders Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Peptide Based Metabolic Disorders Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer